7688 J. Am. Chem. Soc., Vol. 118, No. 33, 1996
Bruzik et al.
1
containing 10 mM EDTA-Na. 31P NMR spectra revealed formation
of only inositol 1-phosphate (within 2% detection limit).
D-Mannito-1-phospho-(1-myo-inositol) (13): H NMR δ 4.07 (tr,
H-2, J ) 2.7 Hz, 1H), 4.0 (m, H′-1, 1H), 3.89 (m, H′-1, 1H), 3.78 (dtr,
H-1, J ) 10.8, 2.8 Hz, 1H), 3.6 (m, 3H), 3.58-3.54 (m, 3H), 3.51-
3.41 (m, 3H), 3.35 (dd, H-3, J ) 10, 2.7 Hz, 1H), 3.12 (tr, H-5, J )
9.3 Hz, 1H); 31P NMR δ 0.99 ppm; ESMS m/z 423.0.
sn-Glycero-3-phospho-(1′-myo-inositol) (4). The solution of 1,2-
dipalmitoyl-sn-glycero-3-phospho-1′-myo-inositol (17 mg, synthesized
as described earlier8 in butanol-methanol-water, 3:5:1) was added
with methylamine/toluene (30%, 0.4 mL) and kept at 55 °C during 3
h. The mixture was diluted with water and extracted with chloroform,
and the aqueous phase was evaporated to dryness. The residue was
redissolved in water and passed through H-form Dowex 50X8-200,
and the eluate was freeze-dried to give the pure diester 4.
L-Idito-1-phospho-(1-myo-inositol) (14): 1H NMR δ 4.23 (tr, H-2,
J ) 2.6 Hz, 1H), 4.02-3.9 (m, H-1′, H-2′, H-1, 4H), 3.84 (m, H-3′,
1H), 3.78-3.6 (m, 6H), 3.53 (dd, H-3, J ) 10.0 Hz, 1H), 3.31 (tr,
H-5, J ) 9.5 Hz, 1H); 31P NMR δ 0.63 ppm; ESMS m/z 423.0.
O-1-(3-Aminopropyl) 1-myo-inositol phosphate (15): 1H NMR δ
4.04 (tr, H-2, J ) 2.4 Hz, 1H), 3.85 (trd, H-1′, overlapped, 2H), 3.75
(ddd, H-2, J ) 2.9, 9.7, 12.4 Hz, 1H), 3.55 (tr, H-6, J ) 9.6 Hz, 1H),
3.46 (tr, H-4, J ) 9.3 Hz, 1H), 3.35 (dd, H-3, J ) 2.5, 10.1 Hz, 1H),
3.13 (tr, H-5, J ) 9.2 Hz, 1H), 2,96 (tr, H-3′, J ) 7.3 Hz, 2H), 1.82 (p,
H-2′, J ) 6.6 Hz, 2H); 31P NMR δ 0.68 ppm; ESMS m/z 317.0.
Cholinephospho-(1-myo-inositol) (16): 1H NMR δ 4.28 (m, H-1′A,
H-1′B, 2H), 4.15 (tr, H-2, J ) 2.8 Hz, 1H), 3.87 (ddd, H-1, J ) 2.8,
8.4, 9.9 Hz, 1H), 3.67 (tr, H-6, J ) 9.7 Hz, 1H), 3.58 (m, H-2′, 2H),
3.56 (tr, H-4, 9.3 Hz, 1H), 3.47 (dd, H-3, J ) 2.7, 10 Hz, 1H), 3.24
(tr, H-5, J ) 9.3 Hz, 1H), 3.13 (s, Me, 9H); 31P NMR δ -1.06; ESMS
m/z 329.9.
4: 1H NMR (500 MHz, signal assignment assisted by 1H-1H COSY)
δ 4.45 (tr, H-2, J ) 2.8 Hz, 1H), 4.2-4.17 (H-1, H-2′, H-3′′, m, 4H),
3.94 (tr, H-6, J ) 9.7 Hz, 1H), 3.8 (dd, H-1′A, J ) 4.5, 11.9 Hz, 1H),
3.84 (tr, H-4, J ) 9.8 Hz, 1H), 3.79 (dd, H-1′B, J ) 6.0, 11.8 Hz, 1H),
3.74 (dd, H-3, J ) 2.8, 10.0 Hz, 1H), 3.52 (tr, H-5, J ) 9.4 Hz, 1H);
13C NMR δ 76.42 (d, J ) 6.1 Hz), 73.93, 72.2, 71.32 (d, J ) 6.5 Hz),
71.15, 70.73, 70.67 (d, J ) 6.7 Hz), 66.52 (d, J ) 5.5 Hz), 62.05; 31
NMR δ 0.14 ppm; ESMS m/z 333.8.
P
O-1-(2-Amino-2-hydroxymethylene-3-hydroxypropyl) 1-myo-
1
inositol phosphate (5): H NMR (500 MHz) δ 4.12 (tr, H-2, J ) 2.8
Hz, 1H), 3.91 (m, H-1′A,B, 2H), 3.85 (ddd, H-1, J ) 2.8, 8.1, 10.9
Hz, 1H, 3.62 (tr, H-6, J ) 9.6 Hz, 1H), 3.6 (m, H-3′, H-4′, 4H), 3.49
(dd, H-4, J ) 9.0, 9.9 Hz, 1H); 3.42 (dd, H-3, J ) 2.8, 9.9 Hz, 1H),
3.20 (tr, H-5, J ) 9.3 Hz, 1H); 31P NMR δ -1.56 ppm.
L-Serine-3-phospho-(1-myo-inositol) (17): 1H NMR δ 4.09 (tr, H-1′,
J ) 5.4 Hz, 2H), 4.04 (tr, H-2, J ) 2.7 Hz, 1H), 3.81 (tr, H-2′, J )
4.29 Hz, 1H), 3.75 (ddd, H-1, J ) 12.00, 9.00, 3.00 Hz, 1H), 3.53 (tr,
H-6, J ) 9.8 Hz, 1H), 3.41 (dd, H-4, J ) 18.6, 9.3 Hz, 1H), 3.35 (dd,
H-3, J ) 10.02, 1.8 Hz, 1H), 3.12 (tr, H-5, J ) 9.3 Hz, 1H); 31P NMR
δ -0.74 ppm; ESMS m/z 346.
O-1-(6-Hydroxyhexyl) 1-myo-inositol phosphate (6): 1H NMR
(D2O) δ 4.23 (tr, H-2, J ) 2.5 Hz, 1H), 3.91 (tr, H-1′, partially
overlapped with H-1, 2H), 3.90 (ddd, H-2, partially overlapped with
H-1′, 1H), 3.73 (tr, H-6, J ) 10.0 Hz, 1H), 3.64 (tr, H-4, J ) 9.5 Hz,
1H), 3.59 (tr, H-6′, J ) 6.5 Hz, 2H), 3.55 (dd, H-3, J ) 3.0, 10.0 Hz,
1H), 3.31 (tr, H-5, J ) 9.5 Hz, 1H), 1.63 (p, H-2′, J ) 7.0 Hz, 2H),
1.55 (p, H-5′, J ) 7.0 Hz, 2H), 1.38-1.35 (m, H-3′, H-4′, overlapped,
4H); 31P NMR δ 0.84; ESMS m/z 359.8.
O-Methyl 1-myo-inositol phosphate (7): 1H NMR δ 4.15 (tr, H-2,
J ) 2.8 Hz, 1H), 3.84 (ddd, H-1, J ) 2.8, 8.2, 9.9 Hz, 1H), 3.65 (tr,
H-6, J ) 9.7 Hz, 1H), 3.56 (dd, H-4, J ) 9.3 Hz, 10 Hz, 1H), 3.52
(dd, Me, J ) 10.8 Hz, 3H), 3.46 (dd, H-3, J ) 2.8, 10.0 Hz, 1H), 3.23
(tr, H-5, J ) 9.2 Hz, 1H); 31P NMR δ 1.1; ESMS 273.6.
O-n-Propyl 1-myo-inositol phosphate (8): 1H NMR δ 4.16 (tr, H-2,
J ) 2.6 Hz, 1H), 3.85 (ddd, H-1, J ) 2.8, 8.3, 10.0 Hz, 1H), 3.76 (q,
H-1′, J ) 6.4 Hz, 2H), 3.66 (tr, H-6, J ) 9.6 Hz, 1H), 3.57 (tr, H-4,
J ) 9.8 Hz, 1H), 3.47 (dd, H-3, J ) 2.7, 9.8 Hz, 1H), 3.24 (tr, H-5, J
) 9.3 Hz, 1H), 1.55 (q, H-2′, J ) 7.3 Hz, 2 H), 0.83 (tr, Me, J ) 7.4
Hz, 3H); 31P NMR δ 0.29; ESMS m/z 301.0 (M - H+).
(Pentaethyleneglyco)phospho-1-myo-inositol (18): 1H NMR δ 4.24
(tr, H-2, 1H), 4.05 (m, CH2OP, 2H), 3.94 (ddd, H-1, 1H), 3.68-3.77
(m, OCH2CH2O, 16H), 3.63 (m, H-4, H-6, CH2OH, 4H), 3.53 (dd, H-3,
1H), 3.31 (tr, H-5, 1H); 31P NMR δ 0.49 ppm; ESMS m/z 479.0 (M -
H+).
(Biotinylpentaethyleneglyco)phospho-1-myo-inositol (19): 1H NMR
δ 4.60 (dd, 1H), 4.42 (dd, 1H), 4.25 (m, CH2OCO, H-2, 3H), 4.05 (m,
CH2OP, 2H), 3.94 (ddd, H-1, 1H), 3.60-3.80 (m, OCH2CH2O, 16H),
3.52 (dd, H-3, 1H), 3.78 (m, 2H), 2.96 (dd, 1H), 2.75 (d, 1H), 2.42 (tr,
2H), 1.32-1.80 (m, 6H); 31P NMR δ 0.44 ppm; ESMS m/z 706.
Glucose-6-phospho-(1-myo-inositol) (20): 5.20 (d, J ) 4.8 Hz),
4.62 (d, J ) 8.0 Hz), 4,23 (tr, J ) 2.7 Hz, H-2, 1H), 4.16 (ddd, J )
5.3, 9.6, 1 Hz), 4.11 (tr, J ) 4.9 Hz), 4.06 (q, J ) 5.3 Hz), 3.93 (m,
H-1, 1H), 3.71 (tr, J ) 9.7 Hz, 1H), 3.61 (tr, J ) 9.7 Hz, 1H), 3.53-
3.43 (m, 3H), 3.29 (tr, J ) 9.4 Hz, 1H), 3.25 (m); 31P NMR δ 0.65
ppm; ESMS m/z 421.4.
1
Uridine-5′-phospho-(1-myo-inositol) (22): H NMR δ 7.89 (d, J
O-n-Butyl 1-myo-inositol phosphate (9): 1H NMR δ 4.20 (tr, H-2,
J ) 2.6 Hz, 1H), 3.88 (trd, H-1′, partially overlapped with H-1, 2H),
3.89 (ddd, H-1, partially overlapped with H-1′, 1H), 3.71 (tr, H-6, J )
9.6 Hz, 1H), 3.61 (tr, H-4, J ) 9.8 Hz, 1H), 3.50 (dd, H-3, J ) 2.8,
10.0 Hz, 1H), 3.28 (tr, H-5, J ) 9.4 Hz, 1H), 1.57 (p, H-2′, J ) 6.7
Hz, 2H), 1.33 (s, H-3′, J ) 7.8 Hz, 2H), 0.87 (tr, H-4′, J ) 7.2 Hz,
3H); 31P NMR δ 0.86 ppm; ESMS m/z 315.5.
O-Allyl 1-myo-inositol phosphate (10): 1H NMR δ 5.95 (m, H-2′,
J ) 5.28 Hz, 1H), 5.33 (dd, H-3′A, J ) 1.1, 17.1 Hz, 1H), 5.19 (dd,
H-3′B, J ) 1.1, 10.5 Hz, 1H), 4.40 (m, 2H), 4.20 (tr, H-2, J ) 2.8 Hz,
1H), 3.90 (ddd, H-1, J ) 2.8, 8.4, 11.1 Hz, 1H), 3.70 (tr, H-6, J ) 9.6
Hz, 1H), 3.61 (tr, H-4, J ) 9.8 Hz, 1H), 3.50 (dd, H-3, J ) 2.8, 10.0
Hz, 1H), 3.28 (tr, H-5, J ) 9.4 Hz, 1H); 31P NMR δ 0.63 ppm; ESMS
m/z 299.4.
O-(2-Hydroxyethyl) inositol phosphate (11): 1H NMR δ 4.18 (tr,
H-2, J ) 2.6 Hz, 1H), 3.88 (ddd, H-1 partially overlapped with H-1′,
1H), 3.68 (m, H-2′, 2H), 3.66 (tr, H-6 partially overlapped with H-2′,
J ) 9.6 Hz, 1H), 3.56 (dd, H-4, J ) 9.4, 9.9 Hz, 1H), 3.47 (dd, H-3,
J ) 2.7, 9.9 Hz, 1H), 3.24 (tr, H-5, J ) 9.3 Hz, 1H); 31P NMR (D2O)
δ 0.14 ppm; ESMS m/z 303.4.
O-1-[(2S)-Hydroxypropyl)] 1-myo-inositol phosphate (12): 1H
NMR δ 4.17 (tr, H-2, J ) 2.9 Hz, 1H), 3.92 (qdd, H-2′ partially
overlapped with H-1, 1H), 3.88 (ddd, H-1, J ) 3.0, 8.5, 10.2 Hz, 1H),
3.81 (ddd, H-1′A, J ) 3.4, 5.7, 10.6 Hz, 1H), 3.66 (tr, H-6 partially
overlapped with H-1′B, J ) 9.3 Hz, 1H), 3.65 (ddd, H-1′B, J ) 6.3,
7.0, 10.6 Hz, 1H), 3.56 (tr, H-4, J ) 9.5 Hz, 1H), 3.46 (dd, H-3, J )
2.8, 10.0 Hz, 1H), 3.24 (tr, H-5, J ) 9.3 Hz, 1H), 1.08 (d, H-3′, J )
6.4 Hz, 3H); 31P NMR δ 0.63 ppm; ESMS m/z 317.7.
) 8.0 Hz, 1H), 5.92 (d, H-1′, J ) 4.7 Hz, 1H), 5.90 (d, J ) 8.0 Hz,
1H), 4.31 (m, H-5′, 2H), 4.2 (m, H-2 overlapped with H-4′ and H-2′,
3H), 4.09 (m, H-3′, 1H), 3.92 (m, H-1, 1H), 3.71 (tr, H-6, J ) 9.6 Hz,
1H), 3.61 (tr, H-4, J ) 9.8 Hz, 1H), 3.50 (dd, H-3, J ) 2.8, 6.0 Hz,
1H), 3.27 (tr, H-5, J ) 9.4 Hz, 1H); 31P NMR δ -0.47 ppm; ESMS
m/z 485.
Transesterification of Ser-Tyr-Ser-Met with IcP. The solution
(50 µL) of tetrapeptide (1 mg) in water was treated with PI-PLC solution
(4 µL, 1 mg/mL). The progress of the reaction was monitored by RP-
HPLC on C18 column using gradient elution as specified earlier. The
reaction was stopped after 48 h and the mixture subjected to LC-ESMS,
using chromatographic conditions as described earlier.
Acknowledgment. We would like to thank Dr. Richard van
Breemen of UIC for generating ES MS spectra, Mr. Robert J.
Kubiak for preparation of biotinylated pentaethylene glycol, and
Dr. T. L. Rosenberry of Case Western University for generous
gift of B. thuriupiensis PI-PLC. This work was supported by
Research Grant GM 30327 from National Institutes of Health
(M.-D.T., S.R., and K.S.B.) and by the Department of Medicinal
Chemistry and Pharmacognosy of UIC (K.S.B. and Z.G.).
Supporting Information Available: 1H and 31P NMR
spectra and ESMS data for compounds 2-23 synthesized in
this work (27 pages). See any current masthead page for
ordering and Internet access instructions.
JA9616084